Addressing large, unmet global markets with innovative proprietary products More »
Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »
Identifying early-stage companies with potential to increase value for shareholders More »
OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights.
OPKO Completes Acquisition of Bio-Reference Laboratories.
OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy more »
OPKO Health Reports 2017 Third Quarter Highlights and Financial Results more »
OPKO Health to Announce 2017 Third Quarter Financial Results on November 8, 2017 more »
OPKO Health is an opportunistic research and development company that targets large, high-growth markets.
FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease click here »